Stock Analysis
Hubei Goto BiopharmLtd First Quarter 2024 Earnings: EPS: CN¥0.03 (vs CN¥0.03 in 1Q 2023)
Hubei Goto BiopharmLtd (SZSE:300966) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥122.2m (up 2.3% from 1Q 2023).
- Net income: CN¥3.55m (down 12% from 1Q 2023).
- Profit margin: 2.9% (down from 3.4% in 1Q 2023).
- EPS: CN¥0.03 (in line with 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hubei Goto BiopharmLtd shares are up 7.3% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for Hubei Goto BiopharmLtd you should be aware of, and 2 of them are concerning.
Valuation is complex, but we're helping make it simple.
Find out whether Hubei Goto BiopharmLtd is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300966
Hubei Goto BiopharmLtd
Hubei Goto Biopharm Co.,Ltd. engages in the research, development, production, and sale of steroid drug raw materials and intermediates in China and internationally.
Mediocre balance sheet with weak fundamentals.